OSOPF yields 2682.25% · JNJ yields 2.14%● Live data
📍 OSOPF pulled ahead of the other in Year 1
Combined, OSOPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSOPF + JNJ for your $10,000?
Osotspa Public Company Limited, together with its subsidiaries manufactures and distributes energy drinks and personal care products worldwide. The company operates in three segments: Beverage, Personal Care, and Others. It offers energy drinks under the M-150, Lipovitan-D, Chalarm, Som in-Sum, White Shark, Shark Energy Drink, and M-Storm brand names; ready-to drink coffee under the M-Presso name; sport drinks under the M-Electrolyte brand; and functional drinks under the Peptein, Peptein Gold, C-Vitt, Calpis Lacto, and Slimma brands. The company also provides baby care products under the Babi Mild brand name; male grooming products under the Exit brand; women beauty care products under the Twelve Plus, Plantstory, Ole Strwaberry, PROhada, and OTG brands; healthcare products under the KRISNAKLAN, Utaitip, Tamjai, YATHAD 4, Yixin, and BANNER brands; and confectionery products under the Botan and Ole brand names. In addition, it provides marketing and property rental services; manufactures and distributes glass, and beverage concentrates and premixes; and distributes food, beverages, and cullet products. Further, the company engages in the import, retail, and wholesale of beverages; investing in other companies; provision of research and development services; electronic commerce business; and education and sale of herbal products. Additionally, it obtains licensing fee for use of trademark, as well as offers manufacturing and distribution services. Osotspa Public Company Limited was founded in 1891 and is based in Bangkok, Thailand.
Full OSOPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.